Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...
Boing Boing on MSN4h
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...
Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...
Monica Johnson, Psy.D., is a clinical psychologist and owner of Kind Mind Psychology, a private practice in NYC that specializes in evidenced-based approaches to treating a wide range of mental ...
As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...
6hon MSN
Many people with thinning hair turn to minoxidil., commonly sold under the brand name Rogaine. But if it doesn’t seem to be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback